Skip to main content
Log in

Alendronate and pharmacological doses of 1α OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia

  • Case report
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Author information

Authors and Affiliations

Authors

Additional information

Received: July 12, 2001 / Accepted: November 28, 2001

About this article

Cite this article

Yamamoto, T., Ozono, K., Shima, M. et al. Alendronate and pharmacological doses of 1α OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia. J Bone Miner Metab 20, 170–173 (2002). https://doi.org/10.1007/s007740200024

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s007740200024

Navigation